Pharmacoeconomic evaluation of Simulect prophylaxis in renal transplant recipients.
Walters
S J
SJ
Sheffield Health Economics Group, University of Sheffield, Sheffield, England.
Whitfield
M
M
Akehurst
R L
RL
Chilcott
J B
JB
D000911:Antibodies, Monoclonal / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000077552:Basiliximab; D001706:Biopsy; D003365:Costs and Cost Analysis; D004311:Double-Blind Method; D004739:England; D006801:Humans; D016030:Kidney Transplantation / Q000191:economics / Q000276:immunology* / Q000401:mortality; D007902:Length of Stay; D010919:Placebos; D011183:Postoperative Complications / Q000145:classification / Q000453:epidemiology; D011993:Recombinant Fusion Proteins / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use; D015996:Survival Rate; D017211:Treatment Failure; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D010919:Placebos; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab